2025 05 02 Owen Yang
Anti-VEGF ocular injection, under the drug group
Ophthalmological anti-neovascularisation agents (#S01L)
in Prescribing in Taiwan, has been funded under the Taiwan National Health Insurance for age-related macular degenetation since 2011.
It is important to be aware that only up to 14 doses in a lifetime can be funded for each eye, equivalent to approximately 2 years of treatment. Treatment beyond this, if needed, is not funded and therefore unlikely to be recorded.
Anti-VEGF ocular injection can also be used in other diseases such as diabetic macular oedema.
Note that similar anti-VEGF (Bevacizumab) has also been used as an anti-neoplastic agent with ATC code #L01FG under a different drug group
Antineoplastic agents, Monoclonal antibodies and antibody drug conjugates (#L01F)
| L01FA01 | not available OTC | |
| L01FA03 | not available OTC | |
| L01FB01 | not available OTC | |
| L01FC01 | not available OTC | |
| L01FD01 | not available OTC | |
| L01FD02 | not available OTC | |
| L01FD03 | not available OTC | |
| L01FE01 | not available OTC | |
| L01FE02 | not available OTC | |
| L01FF01 | not available OTC | |
| L01FF02 | not available OTC | |
| L01FF04 | not available OTC | |
| L01FF05 | not available OTC | |
| L01FG01 | not available OTC | |
| L01FG02 | not available OTC | |
| L01FX05 | not available OTC | |
| L01FX07 | not available OTC | |
| L01FX18 | amivantamab | not available OTC |
L01F Antineoplastic agents, Monoclonal antibodies and antibody drug conjugates (Injections)
Prescribing rates
Prescribing rates
